Made possible by a charitable contribution from
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.
We hope this note finds you doing well on this first day of the summer season!
We’re pleased to provide you with some of the latest
Prostate Cancer News You Can Use
. In addition to the following updates and information that may be of interest to you, the titles of prostate cancer news articles are listed below along with a link to the Us TOO web page that provides access to the full text for each article.
Join us in welcoming
Development Director James Hutson
to the staff at Us TOO! The impact of his work will help us expand the scope of services and resources that we can provide to the prostate cancer community at no charge.
Registration is now open at
15th Annual SEA Blue
rostate Cancer Walk & Run
, which will take place on September 15th in beautiful Lincoln Park.
is an acronym for
dvocate; and blue is to prostate cancer as pink is to breast cancer. Attend in person or register as a virtual mover at no charge if you will not attend in person and want to help fundraise (even from a remote location).
For a glimpse into what makes this event so special for so many people,
check out the video
If you are the wife or female partner of a man with prostate cancer, we invite you to join a conference call to connect with other women facing similar challenges
. Because prostate cancer is a couple's disease, the woman is often subject to her own concerns in addition to those she shares with her partner.
A Forum for Her
is an ongoing series of conference calls and invitation-only Facebook group that provides women with important peer-to-peer support. For more information,
To register, email firstname.lastname@example.org or call 336-842-3578.
Based on the success of
A Forum for Her
and requests for a similar service for the gay community, we are pleased to introduce
A Prostate Cancer Forum for Gay Men and Their Partners
. This ongoing conference call series from Us TOO will provide gay men and their partners with important peer-to-peer support. Calls will begin in late June.
To reserve your spot and get the call-in information, email
or call 336-842-3578.
Prostate cancer support groups provide a valuable opportunity to connect with others for education, support and perspective on managing every aspect of the disease – from testing to active surveillance, treatment options and side effect management.
Us TOO has a network of more than 200 support groups in the U.S. and abroad
. We thank all of the support group leaders and encourage men diagnosed with prostate cancer
to find an Us TOO support group at
No support group in your immediate area?
Us TOO partners with
Answer Cancer Foundation, the first virtual, real time, call-in peer-to-peer support group platform
providing online access from a computer, mobile device or telephone. In addition to calls each month focused on high-risk/recurrent/advanced disease, low-risk/intermediate prostate cancer, AnCan is now hosting an
Active Surveillance Prostate Cancer virtual support group. Calls will be on the first Wednesday of every month at 8:00 pm Eastern
Find details at:
NEWS YOU CAN USE ARTICLES:
Please note that the content below lists only the title of the article rather than a direct link to the content.
For access to the full article
- Men who choose active surveillance for early prostate cancer often don’t follow monitoring rules
- Men choose active surveillance for early age prostate cancer instead of treatment
- Black men less likely than nonblack men to adopt active surveillance
- MRI, ultrasound more accurate in locating prostate cancer, study says
- Biomarker may help identify men with prostate cancer at greater risk of tumor metastasis
- New insights into treatment targets for men with advanced prostate cancers
- Study finds how prostate cancer cells mimic bone when they metastasize
- Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
- ERLEADA® apalutamide Significantly Improved Overall Survival OS and Radiographic Progression-Free Survival rPFS in Patients with Metastatic Castration-Sensitive Prostate Cancer mCSPC
- New Findings from Monash University in Prostate Cancer Provides New Insights (The Influence of Brca2 Mutation On Localized Prostate Cancer)
- Study Findings from Duke University Provide New Insights into Prostate Cancer (An Update of Research Evidence On Nutrition and Prostate Cancer)
- Researchers from University of Western Ontario Provide Details of New Studies and Findings in the Area of Prostate Cancer (A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles)
- Researchers from University of Illinois - Chicago Report on Findings in Prostate Cancer (Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats)
- Researchers from St. Orsola Marcello Malpighi Hospital Discuss Findings in Prostate Cancer (The Human Microbiota and Prostate Cancer: Friend or Foe?)
- Community pharmacies may improve cardiovascular health for prostate patients
- Reports Outline Prostate Cancer Study Findings from National Cancer Institute (Prostate Imaging Reporting and Data System Version 2 for Mri of Prostate Cancer: Can We Do Better?)
- Studies from Spanish National Cancer Research Center in the Area of Prostate Cancer Reported (Brca2 and Other Ddr Genes In Prostate Cancer)
- Researchers from University of Pennsylvania Discuss Findings in Prostate Cancer (Variations In Patterns of Concurrent Androgen Deprivation Therapy Use Based On Dose Escalation With External Beam Radiotherapy Vs. Brachytherapy Boost for Prostate ...)
- Study shows more effective method for detecting prostate cancer
- New Prostate Cancer Findings Has Been Reported by Researchers at University of Pittsburgh Medical Center (Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance)
- Researchers from University of Kentucky Describe Findings in Prostatectomy (Examining and Understanding Value: the Impact of Preoperative Characteristics, Intraoperative Variables, and Postoperative Complications On Cost of Robot-assisted ...)
- PatientPoint and Us TOO International Launch Prostate Cancer Education Campaign
MORE NEWS & CLINICAL TRIALS:
Results from the
, announced at ASCO 2019, showed that ERLEADA® (apalutamide) significantly improved overall survival (OS) and radiographic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
to read the press release.
metastatic castration-resistant prostate cancer
are invited to consider enrollment in one of two international, Pfizer-sponsored studies of talazoparib, a PARP inhibitor:
- TALAPRO-1: A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT) NCT03148795
- TALAPRO-2: A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) NCT03395197
for an overview of these studies in patient-friendly language.
An ASCO 2019 abstract provides data on 221 African American (AA) patients and 1,649 Caucasian (CAU)
patients who received sipuleucel-T
. In terms of all patients, the median overall survival (OS) for AA patients was 35.2 months and the median OS for CAU patients was 25.8 months.
to read more.
Dendreon is currently enrolling men in the
ProVent clinical trial
. This new investigational study will evaluate the effectiveness of sipuleucel-T in
reducing disease progression
in men with lower-risk prostate cancer who are candidates for active surveillance.
to learn more.
The Metastatic Prostate Cancer Project
is a nationwide genomic research study for men with metastatic and/or advanced prostate cancer.
Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries.
is a registry recruiting 5,000 men with advanced prostate cancer from 9 countries.
More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best possible care to enable men to maximize their quality of life.
Take care and enjoy the summer breezes and extra sunshine! Since
June is Men’s Health Month
, it's a great time to talk to friends and family about the importance of prostate cancer awareness and education. Watch for the July 2019 issue of the Us TOO Hot SHEET newsletter next week; and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.
All the best,
Chuck Strand, Chief Executive Officer
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Manager
Connect with Us TOO on Social Media: